NOVO NORDISK BETS ENTIRE BUSINESS ON OPENAI — DRUGS TO SUPPLY CHAIN GOES AI The Danish pharmaceutical giant behind Ozempic has signed a sweeping partnership with OpenAI to embed AI into every layer of its operations — from drug discovery and clinical trials to manufacturing, supply chains, and commercial sales — with full deployment planned by end of 2026. It is one of the largest AI-for-pharma deals ever announced and a signal that AI integration is now a competitive necessity in Big Pharma. Keywords: Novo Nordisk OpenAI partnership, AI drug discovery, pharma AI deal, OpenAI enterprise